CLINICAL PHASE-I STUDY OF NA2B12H11SH (BSH) IN PATIENTS WITH MALIGNANT GLIOMA AS PRECONDITION FOR BORON NEUTRON-CAPTURE THERAPY (BNCT)

被引:69
|
作者
HARITZ, D
GABEL, D
HUISKAMP, R
机构
[1] UNIV BREMEN,DEPT CHEM,W-2800 BREMEN,GERMANY
[2] NETHERLANDS ENERGY RES FDN,ECN,1755 ZG PETTEN,NETHERLANDS
关键词
BNCT; GLIOBLASTOMA MULTIFORME; BORON DETERMINATION TECHNIQUES; BSH PHARMACOKINETICS; BSH BIODISTRIBUTION; BSH TOXICOLOGY;
D O I
10.1016/0360-3016(94)90492-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Within the European collaboration on boron neutron capture therapy (BNCT), a clinical Phase I study is being carried out to establish BNCT as an alternative treatment modality for malignant glioma (WHO III/IV). Data about the pharmacokinetics, biodistribution and toxicity of the boron compound Na2B12H11SH (BSH) are of great importance to avoid radiation damage of healthy tissue and to deliver a sufficient radiation dose. Methods and Materials: Twenty four patients suffering from a glioblastoma multiforme entered the study to date, infused with a maximum concentration of up to 50 mg BSH/kg. Boron concentration measurements in tissues, urine, and blood were carried out, using inductively coupled plasma-atomic spectroscopy (ICP-AES) and quantitative neutron capture radiography (QNCR). A cross-calibration of these boron determination techniques was carried out. Results: In tumor tissue, confirmed by histopathology of small biopsies, we found a consistently high but heterogeneous boron uptake. Necrotic parts contain much lower amounts of boron; normal brain tissue has shown no significant uptake. In skin, bone, muscle, and dura mater only small amounts of boron were found. In blood samples, we found biphasic kinetics, but with variations of the half-lives from patient to patient. The compound is mainly excreted through the urine, but an additional entero-hepatic pathway can be demonstrated. Systematic investigations revealed no toxic side effect of the intravenously administered BSH. Comparable data were obtained by using ICP-AES and QNCR for boron concentration measurements. Conclusion: Taking into account the radiobiological considerations of the neutron beam source, we found promising facts that BNCT could be a useful irradiation method for highly malignant brain tumors. Favorable amounts of the boron compound BSH mere found in tumor tissue, whereas healthy brain tissue has shown no significant uptake.
引用
收藏
页码:1175 / 1181
页数:7
相关论文
共 37 条
  • [1] Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture
    Gabel, D
    Preusse, D
    Haritz, D
    Grochulla, F
    Haselsberger, K
    Fankhauser, H
    Ceberg, C
    Peters, HD
    Klotz, U
    ACTA NEUROCHIRURGICA, 1997, 139 (07) : 606 - 612
  • [2] Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture
    D. Gabel
    D. Preusse
    D. Haritz
    F. Grochulla
    K. Haselsberger
    H. Fankhauser
    C. Ceberg
    H. -D. Peters
    U. Klotz
    Acta Neurochirurgica, 1997, 139 : 606 - 612
  • [3] BORON NEUTRON-CAPTURE THERAPY - BORON BIODISTRIBUTION AND PHARMACOKINETICS OF NA2B12H11SH IN PATIENTS WITH GLIOBLASTOMA
    HASELSBERGER, K
    RADNER, H
    PENDL, G
    CANCER RESEARCH, 1994, 54 (24) : 6318 - 6320
  • [5] Subcellular Biodistribution of Sodium Borocaptate (BSH: Na2B12H11SH) in a Rat Glioma Model in Boron Neutron Capture Therapy
    Teruyoshi Kageji
    Shinji Nagahiro
    Birte Otersen
    Detlef Gabel
    Manekazu Nakaichi
    Yoshinobu Nakagawa
    Journal of Neuro-Oncology, 2002, 59 : 135 - 142
  • [6] Subcellular biodistribution of sodium borocaptate (BSH:: Na2B12H11SH) in a rat glioma model in boron neutron capture therapy
    Kageji, T
    Nagahiro, S
    Otersen, B
    Gabel, D
    Nakaichi, M
    Nakagawa, Y
    JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (02) : 135 - 142
  • [7] Boron neutron capture therapy: Preliminary study of BNCT with sodium borocaptate (Na2B12H11SH) on glioblastoma
    Takagaki, M
    Oda, Y
    Miyatake, SI
    Kikuchi, H
    Kobayashi, T
    Sakurai, Y
    Osawa, M
    Mori, K
    Ono, K
    JOURNAL OF NEURO-ONCOLOGY, 1997, 35 (02) : 177 - 185
  • [8] Boron neutron capture therapy: Preliminary study of BNCT with sodium borocaptate (Na2B12H11SH) on glioblastoma
    Masao Takagaki
    Yoshifumi Oda
    Shin-Ichi Miyatake
    Haruhiko Kikuchi
    Toru Kobayashi
    Yoshinori Sakurai
    Masami Osawa
    Kenjiro Mori
    Koji Ono
    Journal of Neuro-Oncology, 1997, 35 : 177 - 185
  • [9] Boron uptake of BSH (Na2B12H11SH) with time interval from BSH infusion in patients with malignant glioma
    Kageji, T
    Kitamura, K
    Hatanaka, H
    Nakagawa, Y
    ADVANCES IN NEUTRON CAPTURE THERAPY, VOLS I AND II: VOL I: MEDICINE AND PHYSICS, VOL II: CHEMISTRY AND BIOLOGY, 1997, 1132 : B197 - B201
  • [10] SUBCELLULAR B-10 LOCALIZATION IN GLIOBLASTOMA FOR BORON NEUTRON-CAPTURE THERAPY WITH NA2B12H11SH
    HASELBERGER, K
    RADNER, H
    GOSSLER, W
    SCHLAGENHAUFEN, C
    PENDL, G
    JOURNAL OF NEUROSURGERY, 1994, 81 (05) : 741 - 744